Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

17β-Hydroxysteroid Dehydrogenase Type 14 Is a Predictive Marker for Tamoxifen Response in Oestrogen Receptor Positive Breast Cancer

Open access

Abstract

INTRODUCTION: 17β-Hydroxysteroid dehydrogenases (17βHSDs) are important enzymes regulating the pool of bioactive steroids in the breast. The current study was undertaken in order to evaluate implications of 17βHSD14 in breast cancer, measuring 17βHSD14 protein expression in breast tumours. METHODS: An antibody targeting the 17βHSD14 antigen was generated and validated using HSD17B14-transfected cells and a peptide-neutralising assay. Tissue microarrays with tumours from 912 post-menopausal women diagnosed with lymph node-negative breast cancer, and randomised to adjuvant tamoxifen or no endocrine treatment, were analysed for 17βHSD14 protein expression with immunohistochemistry. RESULTS: Results were obtained from 847 tumours. Patients with oestrogen positive tumours with high 17βHSD14 expression had fewer local recurrences when treated with tamoxifen (HR 0.38; 95% C.I. 0.19-0.77, p = 0.007) compared to patients with lower tumoural 17βHSD14 expression, for whom tamoxifen did not reduce the number of local recurrences (HR 1.19; 95% C.I. 0.54-2.59; p = 0.66). No prognostic importance of 17βHSD14 was seen for systemically untreated patients. CONCLUSIONS: Using a highly specific validated antibody for immunohistochemical analysis of a large number of breast tumours, we have shown that tumoural expression levels of 17βHSD14 can predict the outcome of adjuvant tamoxifen treatment in terms of local recurrence-free survival in patients with lymph node-negative ER+ breast cancer. The results need be verified to confirm any clinical relevance.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0040568

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Study design and patient flow chart.
Figure 1 Study design and patient flow chart.CC BY · PubMed Central
Figure 2 17βHSD14 immunohistochemical staining. Tumour tissue representing (A) negative, (B) weak, (C) intermediate, (D) strong immunopositivity. (E) Breast tissue from healthy individual. (F) Tumour section stained with anti-17βHSD14 antibody pre-incubated with a 17βHSD14 peptide.
Figure 2 17βHSD14 immunohistochemical staining. Tumour tissue representing (A) negative, (B) weak, (C) intermediate, (D) strong immunopositivity. (E) Breast tissue from healthy individual. (F) Tumour section stained with anti-17βHSD14 antibody pre-incubated with a 17βHSD14 peptide.CC BY · PubMed Central
Figure 3 Immunoblot analysis of lysates from ZR75-1 and SKBR3 breast cancer cells. Lower bands represent 17βHSD14 at an estimated size of 28 kDa. In lane 1 and 4 cells transiently over-expressing HSD17B14, lane 2 and 5 mock-transfected cells and lane 3 and 6 untreated cells. B-actin serves as a control for equal loading.
Figure 3 Immunoblot analysis of lysates from ZR75-1 and SKBR3 breast cancer cells. Lower bands represent 17βHSD14 at an estimated size of 28 kDa. In lane 1 and 4 cells transiently over-expressing HSD17B14, lane 2 and 5 mock-transfected cells and lane 3 and 6 untreated cells. B-actin serves as a control for equal loading.CC BY · PubMed Central
Figure 4 Kaplan-Meier curves depicting local recurrence-free probability in patients stratified by tamoxifen use. (A) Patients with ER+ tumours and strong 17βHSD14 expression. (B) Patients with ER positive tumours and negative/low or intermediate 17βHSD14 expression. ER = oestrogen receptor, 17bHSD = 17β hydroxysteroid dehydrogenase.
Figure 4 Kaplan-Meier curves depicting local recurrence-free probability in patients stratified by tamoxifen use. (A) Patients with ER+ tumours and strong 17βHSD14 expression. (B) Patients with ER positive tumours and negative/low or intermediate 17βHSD14 expression. ER = oestrogen receptor, 17bHSD = 17β hydroxysteroid dehydrogenase.CC BY · PubMed Central
Figure 5 Kaplan-Meier curves depicting local recurrence-free probability in patients stratified by tumoural 17βHSD14 expression. (A) Local recurrence-free probability of patients with ER positive tumours without tamoxifen. (B) Local recurrence-free probability of patients with ER positive tumours treated with tamoxifen. P-values are generated by log-rank tests. ER = oestrogen receptor, 17bHSD = 17β hydroxysteroid dehydrogenase.
Figure 5 Kaplan-Meier curves depicting local recurrence-free probability in patients stratified by tumoural 17βHSD14 expression. (A) Local recurrence-free probability of patients with ER positive tumours without tamoxifen. (B) Local recurrence-free probability of patients with ER positive tumours treated with tamoxifen. P-values are generated by log-rank tests. ER = oestrogen receptor, 17bHSD = 17β hydroxysteroid dehydrogenase.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 19 references

Cited by

See all 18

Metadata

Authors
Sivik, T., Gunnarsson, C., Fornander, T., Nordenskjöld, B., Skoog, L., Stål, O., & Jansson, A.
Affiliations
  • Linköping University (SE)
  • Karolinska Institutet (SE)
Corresponding author
Sivik, Tove
Venue
PLoS ONE
Published
2012-07-06
Volume
7
Issue
7
Pages
e40568
ISSN
1932-6203 (ISSN-L)
OpenAlex
W1974154390
Cited by
17
References
19
Citations by year
2026: 1 · 2024: 1 · 2022: 2 · 2019: 3 · 2018: 4 · 2017: 3 · 2016: 3
FWCI
0.00
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DiVA (Linkoping University) (submittedVersion, other-oa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Insamlingsstiftelsen Cancer- och Allergifonden
  • Cancerfonden
  • Vetenskapsrådet (K2008-54X-20639-01-3)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Breast Lesions and Carcinomas
Keywords
tamoxifen response, estrogen receptor-positive breast cancer, node-negative breast cancer, local recurrence, predictive biomarkers, adjuvant endocrine therapy, steroid metabolism, antibody validation
MeSH terms
Breast Neoplasms, Female, Humans, Neoplasm Recurrence, Local, Prognosis, Receptors, Estrogen, Tamoxifen, 17-Hydroxysteroid Dehydrogenases, Biomarkers, Treatment Outcome, Antineoplastic Agents, Hormonal, Cell Line, Tumor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: 17β-Hydroxysteroid Dehydrogenase Type 14 Is a Predictive Marker for Tamoxifen Response in Oestrogen Receptor Positive Breast Cancer. https://app.cochat.ai/papers/10.1371/journal.pone.0040568
The paper
Sivik, T., Gunnarsson, C., Fornander, T., Nordenskjöld, B., Skoog, L., Stål, O., & Jansson, A. (2012). 17β-Hydroxysteroid Dehydrogenase Type 14 Is a Predictive Marker for Tamoxifen Response in Oestrogen Receptor Positive Breast Cancer. PLoS ONE. https://doi.org/10.1371/journal.pone.0040568

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.